Drug Discovery

Ivan Kairatov is a titan in the biopharmaceutical sector, recognized for his pioneer work in integrating generative artificial intelligence into the traditional drug discovery pipeline. With a career spanning decades in research and development, Kairatov has been a vocal advocate for moving beyond

The clinical landscape of modern oncology has reached a frustrating plateau where certain aggressive malignancies, despite the advent of revolutionary treatments, remain completely invisible to the human immune system. This persistent invisibility characterizes "immune-cold" environments, where the

The pharmaceutical industry has long grappled with the sobering reality that nine out of ten drug candidates fail during clinical trials, often because the simplistic biological models used in early development do not reflect the staggering complexity of human physiology. For decades, researchers

The sudden cessation of blood flow to the kidneys initiates a cascade of metabolic failures that often results in permanent organ damage despite successful medical intervention to restore circulation. This clinical challenge, known as renal ischemia-reperfusion injury, represents a paradoxical

Ivan Kairatov’s career has been defined by a relentless pursuit of innovation in regenerative medicine and drug development, particularly in the complex landscape of biopharmaceuticals. With a deep background in the mechanics of the human immune system and extensive experience in research and

The global biotechnology sector is currently navigating a period of unprecedented expansion, yet this rapid growth has inadvertently created a massive environmental footprint that many firms are now struggling to address. While these organizations are pioneers of medical and agricultural